FDA Approved: FENSOLVI — Original Application (TOLMAR Inc.)

View source ↗

Summary

FDA approved FENSOLVI (leuprolide acetate) from Tolmar Inc. as an original NDA approval for the treatment of central precocious puberty in pediatric patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• FENSOLVI (Leuprolide acetate)

Snippet

ORIG AP for FENSOLVI (LEUPROLIDE ACETATE)